Corvus Pharmaceuticals (CRVS) Assets Average (2022 - 2025)
Historic Assets Average for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to $85.0 million.
- Corvus Pharmaceuticals' Assets Average rose 3773.75% to $85.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $85.0 million, marking a year-over-year increase of 3773.75%. This contributed to the annual value of $57.2 million for FY2024, which is 58.62% up from last year.
- Latest data reveals that Corvus Pharmaceuticals reported Assets Average of $85.0 million as of Q3 2025, which was up 3773.75% from $74.4 million recorded in Q2 2025.
- Corvus Pharmaceuticals' 5-year Assets Average high stood at $96.9 million for Q2 2022, and its period low was $42.8 million during Q1 2024.
- Its 4-year average for Assets Average is $66.2 million, with a median of $63.5 million in 2023.
- In the last 5 years, Corvus Pharmaceuticals' Assets Average crashed by 4003.13% in 2023 and then soared by 4987.1% in 2025.
- Quarter analysis of 4 years shows Corvus Pharmaceuticals' Assets Average stood at $74.3 million in 2022, then crashed by 34.39% to $48.7 million in 2023, then surged by 31.0% to $63.9 million in 2024, then soared by 33.05% to $85.0 million in 2025.
- Its Assets Average stands at $85.0 million for Q3 2025, versus $74.4 million for Q2 2025 and $64.2 million for Q1 2025.